Mesenchymal Stem Cell-Based Interventions for Bone Fracture Healing in Humans and Animals: A Systematic Review and Meta-Analysis

نویسندگان
doi
10.48309/jmpcr.2026.559799.1900
چکیده

Aim: To evaluate the efficacy and safety of mesenchymal stem cell (MSC) therapy for bone fracture healing in humans and animals, compared with standard treatment, and to identify knowledge gaps for future research. Methods: Systematic review and meta-analysis of studies (2015-2025) identified through MEDLINE, PubMed, Scopus, and Cochrane Library. We included randomized and non-randomized trials in humans and animal models (rats, mice, rabbits, primates) using MSC injections or implants (bone marrow, adipose, or umbilical cord sources) versus standard therapy. Data were extracted independently by two reviewers and analyzed using RevMan Web; risk of bias was assessed with Cochrane RoB-2. Results: Twenty-two studies were included. Meta-analysis showed no significant benefit at 3 months (OR 0.56; 95% CI 0.24-1.30; p=0.18). MSC therapy significantly improved healing rates at 6 months (OR 3.33; 95% CI 1.76-6.29; p=0.0002), 9 months (OR 2.21; 95% CI 1.03-4.74; p=0.04), and 12 months (OR 2.91; 95% CI 1.76-4.81; p<0.0001), with a positive trend beyond 12 months (OR 4.81; 95% CI 0.86-26.86; p=0.07). Bone marrow-derived MSCs exhibited the strongest effect. Adverse events were mild and occurred in <5% of cases; no safety concerns were identified. Conclusion: MSC therapy significantly accelerates fracture union from 6 months onward with an excellent safety profile. Benefits are not evident at 3 months, and long-term data remain limited.